Highlights Vicore Pharma Holding AB

Equities

VICO

SE0007577895

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
19.7 ^SEK	+2.18%		+2.60%	+38.93%

May. 22	Transcript : Vicore Pharma Holding AB - Special Call
May. 20	Vicore Pharma Holding AB Announces Positive Final Results from the Phase 2a Air Trial Demonstrating Buloxibutid Improves Lung Function over 36 Weeks in Patients with Idiopathic Pulmonary Fibrosis	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Vicore Pharma Holding AB Announces Positive Final Results from the Phase 2a Air Trial Demonstrating Buloxibutid Improves Lung Function over 36 Weeks in Patients with Idiopathic Pulmonary Fibrosis	May. 20	CI
Vicore Pharma Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 03	CI
Vicore Announces FDA Breakthrough Device Designation for AlmeeTM, a Digital Therapy for Patients with Pulmonary Fibrosis	Mar. 19	CI
Vicore Pharma Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
Vicore Pharma Holding AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Vicore Pharma Signs Licensing Deal for Idiopathic Pulmonary Fibrosis Drug Candidate	Feb. 09	MT
Alex Therapeutics and Vicore Pharma Announces Positive Results of the COMPANION Study	Jan. 04	CI
Vicore Pharma Holding AB Confirms IPF Development Program on Track and Provides Early-Stage Pipeline Updates	Jan. 02	CI
Vicore Pharma Holding AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Vicore Pharma Holding AB Provides Update Regarding Phase 1 Study of C106	23-10-27	CI
Vicore Pharma Holding AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-24	CI
Vicore Pharma Holding AB Reports Data from EndoPAT® Exploratory Trial	23-08-22	CI
EU Grants Patent to Vicore Pharma's Improved Pulmonary Fibrosis Drug Candidate	23-06-07	MT
Vicore Pharma Holding AB Reports New 36-Week Data from the Air Trial Demonstrating Sustainable Disease Stimulating the Potential of A New Class of Drugs to Stop Disease Propose and Restate in IPF Patients	23-05-19	CI
Vicore Pharma Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
Vicore Pharma Holding AB Initiates Clinical Proof-Of-Concept Study of Endothelial Dysfunction	23-05-03	CI
Vicore Pharma Holding AB Receives Innovation Passport Designation by the UK Regulatory Agency MHRA for C21 in IPF	23-03-29	CI
Vicore Pharma Holding AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-28	CI
Vicore Pharma Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-28	CI
Vicore Pharma Holding AB Announces First Patient Enrolled in COMPANION; a Digital Therapeutic Pivotal Study for Patients with Pulmonary Fibrosis	22-12-05	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Vicore Pharma Holding AB

Equities

VICO

SE0007577895

Highlights

Filters